1,721,470 research outputs found
Supplemental_Figure – Supplemental material for Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
No full textSupplemental material, Supplemental_Figure for Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma by Federica Riccardo, Lidia Tarone, Selina Iussich, Davide Giacobino, Maddalena Arigoni, Federica Sammartano, Emanuela Morello, Marina Martano, Francesca Gattino, Raffaella De Maria, Soldano Ferrone, Paolo Buracco and Federica Cavallo in Therapeutic Advances in Medical Oncology</p
HLA class I antigen defects in maxillary sinus squamous cell carcinoma: potential prognostic significance.
Full text linkElsevier, Nobuyuki, Bandoh ; Takeshi, Ogino ; Tatsuya, Hayashi ; Satoshi, Nonaka ; Yasuaki, Harabuchi ; Naoyuki, Miyokawa ; Soldano, Ferrone, International Congress Series, 1240, 2003, 487-488
autho
Methods for treating a tumor using an antibody that specifically binds HMW-MAA
No full textCombinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-Cell responses against viral or tumor-associated antigens
No full textHuman mesenchymal stem cells (MSC) are immunosuppressive and poorly immunogenic but may act as antigen-presenting cells (APC) for CD4(+) T-cell responses; here we have investigated their ability to serve as APC for in vitro CD8(+) T-cell responses. MSC pulsed with peptides from viral antigens evoked interferon (IFN)-gamma and Granzyme B secretion in specific cytotoxic T lymphocytes (CTL) and were lysed, although with low efficiency. MSC transfected with tumor mRNA or infected with a viral vector carrying the Hepatitis C virus NS3Ag gene induced cytokine release but were not killed by specific CTL, even following pretreatment with IFN-gamma. To investigate the mechanisms involved in MSC resistance to CTL-mediated lysis, we analyzed expression of human leukocyte antigen (HLA) class I-related antigen-processing machinery (APM) components and of immunosuppressive HLA-G molecules in MSC. The LMP7, LMP10, and ERp57 components were not expressed and the MB-1 and zeta molecules were downregulated in MSC either umnanipulated or pretreated with IFN-gamma. Surface HLA-G was constitutively expressed on MSC but was not involved in their protection from CTL-mediated lysis. MSC supernatants containing soluble HLA-G (sHLA-G) inhibited CTL-mediated lysis, whereas those lacking sHLA-G did not. The role of sHLA-G in such inhibition was unambiguously demonstrated by partial restoration of lysis following sHLA-G depletion from MSC supernatants. In conclusion, human MSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL with a limited efficiency, likely because of some defects in APM components. However, they are protected from CTL-mediated lysis through a mechanism that is partly sHLA-G-dependent
Hidden Immunotherapy Targets Challenge Dogma
No full textIntracellular tumor antigen–specific monoclonal antibodies inhibit tumor growth and metastasis and prolong survival of tumor-bearing mice.</jats:p
Human Tumor‐Associated Antigen Mimicry by Anti‐idiotypic Antibodies Immunogenicity and Clinical Trials in Patients with Solid Tumorsa
No full text
- …
